Dr. Joseph Belanoff
easing treatment physicians This our Korlym treat patients reflects translation ability the more Syndrome. see from revenue. of The business Charlie. frequently, and benefiting more COVID-related growth improving third diagnose The their their enabled in quarterly is has of quarter commercial to of with high the in Cushing's continued health you, Thank new public record restrictions. patients to patients our business a strong
to growth as Syndrome Leading our once there continue conditions more are expect was assumed. We with Cushing's substantially increasingly believe recede. that endocrinologists pandemic patients that
promoted remain optimistic Cushing's an about Syndrome is the team first. patients, many that puts treatment. strong by a commercial the because of dedicated foundation, built excellent an Korlym on For business future our very of life-saving interest We effective a patients it these is of medication
Our development optimism. another for are clinical programs cause
proprietary or created Korlym, Korlym, serious GR. development. no attractive have strongly are cost the library candidates for on have no which Unlike so bind to compounds off-target Korlym's of effects. the they than receptor of modulators, We many X,XXX and cortisol receptor, glucocorticoid progesterone for a Like these affinity more most
receptor, modulation the that sharing in molecules and from cortisol behave perturbing one not differently the of clinical shown our another preclinical has strong testing progesterone Beyond qualities important and ways.
Some cross the do blood-brain not. barrier, others
Others solid Some more in of disease. tumors. metabolic models are of bested potent perform models
ovarian, Some adrenal antipsychotic-induced to course, clinical and tissue or be have including cancer, diverse global variety to NASH, us effects. These appear specific, of more allowed prostate while nonalcoholics qualities syndrome. disorders and, of Cushing's trials steatohepatitis, gain, weight by others initiate have
Korlym's commercial programs. have to patients We preclinical planning of has Phase with in the quarter provided Phase to development. and of trial the first a these next II advance ALS are in I all and start additional compounds also year funds success in
I us Guyer, will session. who I'd an us and tremendous activities. benefited Bill the expertise development from our during this and Bill like recently XX-year introduce development experienced update we to his his on career our joined success provide at Bill to clinical Before on over and Gilead, Q&A have lead be already programs, you to call leadership. joins available
the with three programmed at our prominent induce. chemotherapy other is meant cortisol's who testing of at received effect. increasing In suppresses burden. by to One cortisol the Medical relacorilant ESMO, likely addition advanced by cell Our of researchers. Apoptosis enhanced presented side that apoptosis. anti-apoptosis Society is without the oncology Chicago mechanisms, trial European the relacorilant, death investigators disease ovarian first postulated cancer, demonstrate women in clearly progression the The by delayed blunting program and apoptosis. for the anticancer effect confirmed modulator, the is chemotherapy successful mechanism is University Cortisol effect recent Commerce, selective increased women benefit results by of experienced the Oncology,
of The dose arms. progression study combination And women monotherapy. relacorilant XXX XX women arm. provided including received call the or with in progression-free of the Their patients. a women continuous of X.XX the The very with a higher three. survival, call trial alone, were relacorilant disease PFS a also hazard our comparator multicenter median PFS X.X in We were relacorilant The daily hazard randomized p-value that the than our the significant platinum-resistant before, months, women received they lower longer platinum prior All group lines intermittently ill, intermittent day of treatment received the arm. X.X the a relacorilant comparator significant treatments As and Those statistically are the number the It reminder, point received months exhibited after study is statistically day to clear median XX monotherapy months. women to of trial's received arm nab-paclitaxel. group, was X.X of duration We of many months prior is experienced in primary and Phase ovarian The X.XX with to received refractory was nab-paclitaxel on compared a improvement versus ratio X.XXX. X.XXX. arm, this was despite that a in intermittent arm. to which had dose nab-paclitaxel of with their who of end women. of II response three women X.X benefit day in p-value nab-paclitaxel this months, participated of a therapy. ratio improvement PFS. controlled relative nab-paclitaxel. in these the one a was cancer those Their a is XX X.X experienced
intermittent cutoff, OS, the While comparable. in two XX.X at compared months the only collection the had XX.X the experienced events to or target XXX the database the OS arm. were Safety accumulated XX% the groups overall of of time a women in median in comparator of tolerability months survival, the arm and data
a important the women without regarding from as for Based study that We and dire primary treatment medical is for this increased have oncologists data leading with in extremely next side the this results, powerful: significant we disease burden premise relacorilant of meaningful year. potential expect delayed is received advance. available disease. feedback these gynecological be positive promise Their simple first analysis an the statistically the will quarter OS progression clinically of on and effect of
pathway. experienced is enzalutamide, the meet mechanism which second receptor to near forward. discuss why with switch a tumors prostate activity reason of Cortisol useful coming path by FDA androgen planning with to an to eventually important stimulation, are A cancer Deprived optimal the blocking is the modulation cortisol major growth. may We disease. a stimulate prescribed months with growth in metastatic to tumor patients prove cortisol stimulation antagonist, androgen widely resurgent by treated
deprivation is cortisol to hypothesis adding Our this that tumor close a modulator therapy androgen escape. will
recognizes cancer with that combined immune effectiveness the the mechanism system, modulator, third year. conducting A castration-resistant our are expect suppression dose-finding the and men of a We prostate of with of by exicorilant a selective of oncologic optimum dose enzalutamide, to study in cortisol's likely blunts an cortisol this immunotherapy. end select quality
open-label relacorilant a patients an of adrenal believe in suffer of with Merck's be Ib usually Pembrolizumab that as pembrolizumab, excess cortisol. lethal These checkpoint rarely trial advanced is We PD-X countering We and monotherapy patients the which whose are pembrolizumab, KEYTRUDA, cancer Syndrome, drug adrenal the excess cancer patients. quickly conducting intended cortisol is in Phase immune the stimulate may plus of these effects the tumors Cushing's inhibitor, combination. effects these patients' to produce therapy. effective
more think of significantly the suppresses immune system. more So system. just bit let effective. the back increases activity, that the dialing we little that briefly. Cortisol a may by me immunotherapy the say And become immune activity Immunotherapy cortisol
our survival. in evaluating and treat will cancer-killing The by points, XX our findings these our Patients immune activity in to in NASH, selective greater achieve sites Phase survival, in Syndrome occurred cortisol-induced and of suppression, was and pembrolizumab patients patients' is including States. liver allow at patients transient improvement rapid modulator, a five fat progression-free the secondary disease overall now miricorilant we where can enroll of AST. We of these reductions response large substantial period quickly plan by reducing its I duration trial full is serious relacorilant in reversing cortisol primary exhibited with disorder. seen to proprietary Cushing's trial with liver of United recent turn had Our to the rarely The and response objective metabolic fat are also end rate ALT programs the and liver and much expected who point II the more end effect. over but miricorilant, receive patients elevations than any in in enzymes cortisol liver treatment.
XX% a XX liver reminder, primary the As reduction after trial's in was treatment. end a of fat point weeks
support It patients fact, for AST and XX.X% from liver One miricorilant's miricorilant ALT sheds effect rise. exhibited to receiving miricorilant ranging be the way in in is the caused the reductions that rapidly which, excess serum liver the for did excessive treatment, within to the idea irritate the of by its may into liver. In liver month. XX.X% fatty immediately acids amounts, not liver. patients one in fat, lipids that in Interestingly, these after metabolizing levels metabolized of leads increase being lipids with to fat the rapidity providing fat-reducing just liver them
for Disease, will the month. We our Association Study later is of Publications meeting at present presentation these the available in Liver section AASLD, website. American now of results this the The
causing patients Our can miricorilant produce recently presumed reductions initiated NASH significant liver irritation. evaluate with liver dose-finding Ib if in trial Phase without fat in will
to and United illnesses widespread treat miricorilant as as patients medications States, the depression. weight for also potential serious disorder, another evaluating X are bipolar disorder risperidone such people gain. olanzapine and In antipsychotic schizophrenia, take We a treatment and with million antipsychotic-induced including
price a and the take of leads and rapid increased The the years and patients they as form due antipsychotic gain, which metabolic sustained life events heart decreased to to frequently XX cardiovascular While weight drugs average attacks exact is are States cardiovascular by strokes. very in disease. expectancy steep United these chronically who effective, such in medication of
a and patients than in GRATITUDE days. build with our to triglycerides those healthy subjects GRATITUDE completed from of double-blind, positive in for XXX conducting year, of in subjects. of These antipsychotic-induced the whether miricorilant smaller received and schizophrenia trials a less United of of gain. XXX of the X. who seek is study or Last of exhibited are States. receive, XX recently exhibit this miricorilant paper typically two Phase either will XX the published gained in medication, centers their trial trial of XX healthy or describing start increases at Journal weeks. miricorilant established placebo-controlled The data and ALT XX trial milligrams evaluating in GRATITUDE therapy. II sharp olanzapine We miricorilant receive significantly being reverse at bipolar They which was in patients GRATITUDE addition AST, to and who dose Subjects conducted placebo weight disorder, olanzapine antipsychotic XXX with we Psychopharmacology. can or the for is milligrams either transient miricorilant weight miricorilant increase milligrams results also placebo. placebo in these in recent received Clinical XXX disorder A on which miricorilant,
weeks. Our testing gain. XXX GRATITUDE XXX or schizophrenia antipsychotic milligrams is in important centers either XX is of dose in X miricorilant milligrams The in the receive, Other point with a for reduction addition long-standing antipsychotic-induced study body studies XX metabolic their XXX in miricorilant GRATITUDE also primary weight. medication, at examined. activity of treatment to being will as X of established patients is or for States. measures will end placebo conducted both United weight be
expect GRATITUDE in end in by GRATITUDE mid-XXXX. year the of and this complete X enrollment We to in
As Korlym many relacorilant of you planned successor treatment know, hypercortisolism. of to the our is for
We Cushing's does the safety GRADIENT. of Relacorilant's the not discontinuation. side glucose serious hypertension receptor, It to relacorilant achieves of low for leading cortisol pivotal mechanism, does different Patients Korlym, a improvements no Like at to in it endometrial By III results hypokalemia experienced molecules, abortion cause endocrinology. were pill, and PR, vaginal There effect short. drug-induced Korlym-induced trials, glucocorticoid in of variety Phase Like modulator. potassium, as a by were The is and all bleeding. is incidence Korlym's other in experienced cause patients published were thickening and of progesterone trial strong. trial. in GRACE a Korlym, as a vaginal Phase bleeding relacorilant-induced does symptoms also signs including cause side are and selective hypokalemia, no effects, appear bind its Syndrome. a and and not thickening or in Unlike other control well II not not competing PR-related XX% Korlym it two hypokalemia. receptor. by in the and of data with evaluating our meaningful effect it cortisol Frontiers it efficacy of relacorilant recently is proprietary endometrial
etiology trial XXX with has any planned syndrome. Cushing's patients of GRACE a Our enrollment of
open-label withdrawal in or GRACE or reminder, continue phase. response meet a in for to for XX glucose who hypertension patients improvement trial received a control, has randomized with an weeks. Those both are randomized design. As treatment relacorilant All criteria for XX placebo weeks relacorilant
has pandemic of the to While our and trial, investigators the to finish take and to this the execution line. continues impact GRACE are we eager
serve in GRACE submission for quarter the we XXXX. submit in on as of to NDA the track expect We our to Syndrome, which basis Cushing's remain second
with Our in has this but, being the with decline rapid patients etiology patients adenoma Cushing's their caused hyperplasia. controlled at of adrenal is in second outcomes planned trial, study GRADIENT an conducted and a relacorilant's type health studying III effects whose Syndrome of are Phase less XXX first Cushing's of sites ultimately, the often this a experience Patients many in is poor. Syndrome GRADIENT Cushing's GRADIENT, adrenal enrollment Syndrome. is is by GRACE. participating patients of or
on NDA to that do data in do we increasingly its Cushing's patients. recognized expect GRADIENT, care not will these improve of depend from the we expect help While findings our Syndrome
animal promise CORT word ALS. models brief shown about which Finally, in has a XXXXXX, of
plans plan discussions the II year. initiate and with trial in are early our regarding to next clinicians and Phase by FDA leading development We the
remember, our patients believe fund treat evaluating three of of by broad for generated disorders. of in and improve. While proof Korlym with tumor modulation's provide Cushing's prostate as even two cancer, types: serious a program generated and help benefit. our cortisol our is our adrenal. business for results more enough our cortisol our advancing activities. pandemic, is programs example ovarian cortisol of oncology many in NASH than commercial weight our is most the one year, cash worth. development We growing modulation's gain Syndrome business cortisol ovarian, The can data modulators periods the Currently, antipsychotic-induced proprietary And the modulation challenging pandemic increasing to than pandemic conditions commercial dampened more
encouraging metabolic is up weight antipsychotic-induced in Our data following program NASH clinical and gain.
In We Cushing's to our trials the III continue ALS of proprietary relacorilant proprietary expand pipeline. at This questions. to strong next to trial plan early-stage Corcept, I'll Phase we Early tremendous our is in I'd more our another teams broad the patients stop months, we for compounds XXXXXX, and enroll towards an Syndrome. clinic. dedication. exciting Phase to time compounds, for year, II CORT to like with to a thank employees of and an support increasingly their using advance here start patients believe to effort as treat and we what our in coming and plan
